* Pharvaris NV PHVS.OQ PHVS.O is expected to show no
change in
quarterly revenue when it reports results on April 3
(estimated) for the period ending December 31 2023
*
* LSEG's mean analyst estimate for Pharvaris NV is for a
loss
of 53 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and 1 "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Pharvaris
NV is
$35.00, above its last closing price of $23.11.
Previous quarterly performance (using preferred earnings measure
in euros).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Sep. 30 2023 -0.59 -0.60 -0.58 Beat 3.4
Jun. 30 2023 -0.59 -0.65 -0.63 Beat 3.1
Mar. 31 2023 -0.74 -0.74 -0.67 Beat 9.9
Dec. 31 2022 -0.68 -0.65 -1.17 Missed -79.4
Sep. -0.63 -0.63 -0.25 Beat 60.5
30 2022
Jun. 30 2022 -0.57 -0.56 -0.38 Beat 31.8
Mar. 31 2022 -0.43 -0.49 -0.48 Beat 2.7
Dec. 31 2021 -0.99 -0.71 -0.09 Beat 87.3
This summary was machine generated April 1 at 10:55 GMT. All
figures in euros unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)